Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM). In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been ...
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM). In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been ...
Introduction and objectives Dabigatran is an anticoagulant drug and a direct thrombin inhibitor and has been approved for the prevention of ischemic stroke secondary to nonvalvularauricular auricular fibrillation. The aim of this study was to determine the efficacy of dabigatran in clinical practice for...
For pediatric patients currently receiving a parenteral anticoagulant, start PRADAXA Oral Pellets 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug (e.g., intravenous...
Dabigatran etexilate mesylate is an anticoagulant drug. Dabigatran demonstrated its efficacy for prophylaxis and treatment of thromboembolic event during orthopaedic surgery and curative treatment of hypercoagulability in atrial fibrillation. The present study deals with the development and...Pintu...
but significant drug-drug interactions when used in combination with strong P-glycoprotein inducers or inhibitors such as amiodarone or rifampicin. It has also been associated with lower rates of stroke and systemic embolism than warfarin, a comparable anticoagulant. Dabigatran etexilate is an inhibitor...
Warfarin is an anticoagulant used to prevent heart attacks, strokes, and blood clots. Learn about ... Reviews & ratings 8.1 / 10 56 Reviews View more WarningsDo not stop taking dabigatran without your doctor's advice. Stopping it suddenly can increase your risk of blood clots or stroke.Som...
Pediatric Patients: Avoid use in children with eGFR (Schwartz) <50 mL/minute per 1.73 m2 due to risk of increased drug exposure. Discontinue in patients who develop acute renal failure while on therapy; consider an alternative anticoagulant....
In Vivo:Dabigatran (0.01-0.1 mg/kg; i.v.) inhibits clot formation with an ED50of 0.033 mg/kg in Wessler model. 相关产品:Drug Repurposing Compound Library Plus|FDA-Approved Drug Library Plus|Bioactive Compound Library Plus|Edoxaban tosylate|Argatroban monohydrate|15,16-Dihydrotanshindiol C|Edoxaba...
Dabigatran warning.Dabigatran warning.The article reports on the warning for General Practitioners (GPs) that they must assess renal function before prescribing the new anticoagulant drug, dabigatran, and must not give it to patients with severe renal impairment.EBSCO...